Kaleido Biosciences, Inc. is a clinical-stage healthcare company focused on leveraging the potential of the microbiome organ to treat disease and improve human health. Its Microbiome Metabolic Therapies (MMTs) is designed to drive the function and distribution of the microbiomes existing microbes in order to decrease or increase the production of metabolites to certain bacteria in the microbiome community. The Company is also advancing a broad pipeline of MMT candidates with the potential to address a variety of diseases and conditions with unmet patient needs. The Company utilizes its discovery and development platform to study MMTs in microbiome samples to rapidly advance MMT candidates into clinical studies in healthy subjects and patients. Its KB195 is the lead MMT candidate for development in the treatment of patients with urea cycle disorders. The Company is conducting a Phase II clinical trial under an Investigational New Drug Application (IND).
Number of employees : 82 people.
|Vote ||Quantity||Free-Float||Company-owned shares||Total Float
|Flagship Pioneering ||19,575,710||
|Fidelity Management & Research Co. LLC ||3,693,930||
|HarbourVest Partners LLC ||1,833,832||
|Michael Bonney ||1,579,676||
|The Vanguard Group, Inc. ||993,183||
|Federated Global Investment Management Corp. ||825,000||
|Palo Alto Investors LP ||786,400||
|Baillie Gifford & Co. ||721,512||
|Invus Public Equities Advisors LLC ||500,500||
|SSgA Funds Management, Inc. ||443,804||
|Company contact information|
Kaleido Biosciences, Inc.
65 Hayden Avenue
Lexington, MA 02421
Phone : +1.617.674.9000
Web : http://www.kaleido.com
Sector Other Biotechnology & Medical Research
Connections : Kaleido Biosciences, Inc.